HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) traded down 3.2% during trading on Monday . The stock traded as low as $2.73 and last traded at $2.73. 200 shares were traded during trading, a decline of 76% from the average session volume of 850 shares. The stock had previously closed at $2.82.
HLS Therapeutics Trading Down 3.2 %
The firm has a 50-day moving average of $2.64 and a 200 day moving average of $2.53.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
- Five stocks we like better than HLS Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- How to Invest in Small Cap Stocks
- Trading Stocks: RSI and Why it’s Useful
- These Are the Dividend Stocks Insiders Bought in January
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
